Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 2, 2026

Social Security capped at $50,000? ‘Crisis in the near horizon’ forces painful solution with new proposal. Do this now

View original at finance.yahoo.com
Social Security capped at $50,000? ‘Crisis in the near horizon’ forces painful solution with new proposal. Do this now Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Six-figure Social Security payouts are limited to couples who earned at or above the program's taxable maximum for decades and waited until full retirement age to claim

    60% confidence
  • Nearly 50% of Americans are making one big Social Security mistake

    60% confidence
  • Social Security trust fund is projected to run dry within the next six years, potentially forcing automatic cuts if lawmakers fail to act

    60% confidence
  • Benefit payments for older Americans could be reduced by 24% as of 2032 due to the One Big Beautiful Bill Act accelerating fund collapse

    60% confidence
  • There is a trust fund crisis in the near horizon for Social Security

    60% confidence
  • An income security program designed to keep seniors out of poverty and ensure adequate retirement income should not be paying six figures

    60% confidence

Data points we hold from this source

Social Security Administration · projected benefit reduction24 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com